Volume 16 Supplement 1

Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Open Access

Natriuretic peptides and cGMP in metabolic disease

BMC Pharmacology and Toxicology201516(Suppl 1):A7

DOI: 10.1186/2050-6511-16-S1-A7

Published: 2 September 2015

The cardiac natriuretic peptides ANP and BNP stimulate adipocyte metabolism to increase lipolysis of triglycerides to free fatty acids, as well promote brown adipocyte energy expenditure through uncoupled mitochondrial respiration. Energy expenditure in brown adipocytes holds potential for improving cardiometabolic disease by consuming glucose and fatty acids and thereby improving insulin sensitivity. This presentation will describe studies in mouse models lacking the natriuretic peptide ‘clearance receptor’ Nprc (gene = Npr3) in adipose and other tissues, as well as more clinically oriented studies in human subjects examining a role for the natriuretic peptide system in insulin sensitivity and energy expenditure. We will also describe novel signal transduction mechanisms downstream of PKA and PKG that promote the increase in brown adipocytes within white adipose tissue and their metabolic activation.

Authors’ Affiliations

(1)
Sanford-Burnham Medical Research Institute

Copyright

© Collins et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement